FDA is smashing the status quo for regulatory science - STAT

FDA is smashing the status quo for regulatory science - STAT

Opinion: FDA is smashing the status quo for regulatory science

By PETER J. PITTS

ADOBE

At the FDA, centralizing new drug policy in the reorganized Office of New Drug Policy will help the agency be a leader in regulatory science.

READ MORE